Similarly, among selpercatinib treated RET+ CRC patients, the ORR was (20%, 2/10) markedly lower compared to the ORR of 69% in patients with RET fusion‐positive non‐small cell lung cancer(NSCLC) and 79% in patients with RET fusion‐positive medullary thyroid cancer, as reported in the LIBRETTO‐001 trial [9]. The gene discussed is RET; the disease is lung cancer.